Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia

Larimar Therapeutics, Inc. announced preliminary top-line data from the 25 mg cohort of its Phase 2, four-week, placebo-controlled, dose exploration trial of CTI-1601 in participants with Friedreich's... | May 16, 2023

Related Keywords

,Larimar Therapeutics Inc ,Larimar Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Marimar ,Nnounced ,Reliminary ,Data ,Rom ,The ,5 ,G ,Cohort ,F ,Its ,Hase ,Nose ,Exploration ,Trial ,N ,Participants ,Ith Lrmr Us5171251003 ,